PureTech Health
PureTech Health
PRTC
LSE
127.00
GBX
0.95%
About
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval.
Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors.
SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 424.4K |
| Three Month Average Volume | 8.8M |
| High Low | |
| Fifty-Two Week High | 2.385 GBX |
| Fifty-Two Week Low | 1.39 GBX |
| Fifty-Two Week High Date | 05 Jun 2024 |
| Fifty-Two Week Low Date | 11 Dec 2023 |
| Price and Volume | |
| Current Price | 1.63 GBX |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -2.24% |
| Thirteen Week Relative Price Change | -31.25% |
| Twenty-Six Week Relative Price Change | -26.00% |
| Fifty-Two Week Relative Price Change | -27.05% |
| Year-to-Date Relative Price Change | -22.39% |
| Price Change | |
| One Day Price Change | -1.93% |
| Thirteen Week Price Change | -30.34% |
| Twenty-Six Week Price Change | -19.31% |
| Five Day Price Change | -1.81% |
| Fifty-Two Week Price Change | -17.76% |
| Year-to-Date Price Change | -16.07% |
| Month-to-Date Price Change | -6.11% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.30051 GBX |
| Book Value Per Share (Most Recent Quarter) | 1.0051 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.29797 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.00222 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.36874 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00911 GBX |
| Revenue Per Share (Trailing Twelve Months) | 0.0013 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend Per Share (5 Year) | -99999.99 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.17967 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.22919 GBX |
| Normalized (Last Fiscal Year) | -0.28951 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.17967 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.22919 GBX |
| Including Extraordinary Items (Last Fiscal Year) | -0.17967 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | -0.22919 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.92136 GBX |
| Cash Per Share (Most Recent Quarter) | 1.59755 GBX |
| Cash Flow Per Share (Last Fiscal Year) | -0.16873 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | -0.23965 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.33603 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,207 |
| Cash Flow Revenue (Trailing Twelve Months) | -25,849 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -16,536.11% |
| Pretax Margin (Last Fiscal Year) | -1,084.17% |
| Pretax Margin (5 Year) | 534.62% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -2,534.90% |
| Operating Margin (Trailing Twelve Months) | -29,152.56% |
| Operating Margin (5 Year) | 46.11% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -2,000.84% |
| Net Profit Margin (Trailing Twelve Months) | -19,222.22% |
| Net Profit Margin (5 Year) | 352.67% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 11.85% |
| Tangible Book Value (5 Year) | 11.20% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -90.86% |
| Revenue Growth (3 Year) | -30.64% |
| Revenue Change (Trailing Twelve Months) | -96.01% |
| Revenue Per Share Growth | -30.88% |
| Revenue Growth (5 Year) | -34.35% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -44.10% |
| Total Debt (5 Year) | 16.11% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -72.39% |
| EPS Change (Trailing Twelve Months) | -80.86% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -364,186,400 |
| Net Debt (Last Fiscal Year) | -231,166,600 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 154 |
| Price to Sales (Trailing Twelve Months) | 1.1K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 604 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 2 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 4 |
| Long Term Debt to Equity (Most Recent Quarter) | 5 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -80,879,520 |
| Free Cash Flow (Trailing Twelve Months) | -92,163,280 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 5 |
| Total Debt to Equity (Most Recent Quarter) | 8 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -9.54% |
| Return on Assets (Trailing Twelve Months) | -14.13% |
| Return on Assets (5 Year) | 4.92% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -13.06% |
| Return on Equity (Trailing Twelve Months) | -19.88% |
| Return on Equity (5 Year) | 8.81% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -10.67% |
| Return on Investment (Trailing Twelve Months) | -16.35% |
| Return on Investment (5 Year) | 5.94% |